.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

TRK Inhibitors: Precision Medicine in Oncology

EP. 1: Precision Medicine in Solid Tumor Malignancies

April 19th 2019

EP. 2: Significance of TRK Inhibitors for Solid Tumors

April 19th 2019

EP. 3: Precision Medicine for Solid Tumors: Where We Are Headed

April 19th 2019

EP. 4: NTRK Gene Fusions in Solid Tumor Malignancies

April 19th 2019

EP. 5: Precision Medicine: Identifying Actionable Biomarkers

April 19th 2019

EP. 6: Detecting NTRK Gene Fusions

April 19th 2019

EP. 7: TRK Inhibitors for Solid Tumors: Overview

April 19th 2019

EP. 8: Larotrectinib for Solid Tumors With NTRK Gene Fusions

April 19th 2019

EP. 9: Entrectinib as Treatment for NTRK-Positive Solid Tumors

April 19th 2019

EP. 10: Managing Patients on TRK Inhibitors

April 19th 2019

EP. 11: Genomic Testing: GI Tumors

April 19th 2019

EP. 12: Genomic Testing: Sarcoma, Lung Cancer and Thyroid Cancer

April 19th 2019

EP. 13: Genomic Profiling in Solid Tumor Malignancies: Challenges

April 19th 2019

EP. 14: Precision Medicine in Oncology: Overcoming Obstacles

April 19th 2019